← Back to Search
First Line Chemotherapy Of Metastatic Breast Cancer.
P. Pronzato, M. Rondini
Published 2006 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
In the last 20-30 years the approach to metastatic breast cancer by chemotherapy has been largely studied. Anthracyclines, taxanes and, more recently, capecitabine and gemcitabine represent the breakthrough of treatment. In the next future the combination of chemotherapy and target therapy will be considered more frequently.
This paper references
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.
J. Nabholtz (1999)
Chemotherapy for metastatic disease: current status.
J. Graham (2005)
Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy
J. M. Nabholtz (1999)
The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer.
F. Holmes (1993)
Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial.
J. Abrams (1995)
Metastatic breast cancer: higher versus low dose maintenance treatment when only partial response or a no change status is obtained following doxorubicin induction treatment
G Falkson (1992)
Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy
J. Bitran (1983)
Final results of a phase II study of weekly trastuzumab and vinorelbine in chemonaive patients with HER2-overexpressing metastatic breast cance.
G. Bernardo (2004)
Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first‐line doxorubicin‐containing chemotherapy
J. Pierga (2001)
[Treatment of metastatic breast cancer].
J. Yahalom (1986)
Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall surviva.
K. Albain (2004)
Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
R. Fossati (1998)
[Treatment of breast cancer in males].
E. Waugh (1995)
Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association.
H. Muss (1991)
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy
A. Gennari (2004)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
M. Marty (2005)
Taxane containing regimens for metastatic breast cancer.
D. Ghersi (2003)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer.
M. Venturini (1996)
Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy: A subset analysis of CALGB study 8081
C. Kardinal (1988)
Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.
V. Valero (1997)
Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centres
M. Dowsett (2003)
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
V. Valero (1995)
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.
A. Seidman (1995)
Maintenance paclitaxel vs. control after anthracycline/paclitaxel combined first-line chemotherapy in MBC. Final results from the Italian MANTA1 study
A Gennari (2005)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
C. Vogel (2002)
Herceptin® Alone or in Combination with Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Pivotal Trials
J. Baselga (2001)
Results and long term follow‐up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin‐containing chemotherapy
Z. Rahman (1999)
[Prognostic factors in the response of a first line chemotherapy in advanced breast cancer].
F. Chauvin (1990)
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer.
J. Nabholtz (1996)
Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group.
J. Bonneterre (1993)
Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy
P. Valagussa (1986)
Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study
S. L. Chan (2005)
Disease of the breast
C. W. Elston (1998)
Treatment of metastatic disease of the tibia.
C. Kelly (2003)
Treatment of breast cancer.
G. Hortobagyi (1998)
Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.
F. Holmes (1991)
Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens.
R. A'hern (1993)
The combination of trastuzumab and vinorelbine as a atractive regimen in overexpressing metastatic breast cancer patients
I. Głogowska (2005)
USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER 2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER 2
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.
J. O'Shaughnessy (2002)
Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherpy for breast cancer
J Bonneterre (1993)
Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study.
G. Falkson (1995)
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
P. Ravdin (1995)
Management of breast cancer patients failing adjuvant chemotherapy with adriamycin‐containing regimens
A. Buzdar (1981)
Assessment of clinical benefit with trastuzumab plus chemotherapy (CT) in patients with Her2-positive (HER2+) metastatic breast cancer not achieving objective responses
M Pegram (2004)
Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment.
G. Falkson (1998)
Metastatic breast cancer: higher versus low dose maintenance treatment when only a partial response or a no change status is obtained following doxorubicin induction treatment. An Eastern Cooperative Oncology Group study.
G. Falkson (1992)
This paper is referenced by
Comparative Studies on the Antitumor Effect of Artemisinin, Artesunate and Artemether Against Stage II Breast Cancer in Animal Model
Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs.
L. Marconato (2008)
NGlycolylGM3/VSSP Vaccine in Metastatic Breast Cancer Patients: Results of Phase I/IIa Clinical Trial
A. de la Torre (2012)
Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial
A. Welt (2016)
Comparative analysis of xanafide cytotoxicity in breast cancer cell lines
N. Alami (2007)
Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
G. Arpino (2015)
Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer
I. Alvarez-Lopez (2020)
Vinorelbine and capecitabine in anthracycline- and/or taxane-pretreated metastatic breast cancer: sequential or combinational?
J. Zhang (2012)
Integrative Bioinformatics Analysis Reveals Potential Target Genes and TNFα Signaling Inhibition by Brazilin in Metastatic Breast Cancer Cells
A. Hermawan (2020)
The role of JNK2 and JNK1 in breast cancer mediated invasion and metastasis
Azadeh Nasrazadani (2010)
Treatment with Cisplatin and Etoposide Chemotherapy in Patient with Metastatic Breast Cancer
M. Kim (2017)
Treatment patterns and duration in post-menopausal women with HR+/HER2− metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004–2010)
A. Macalalad (2015)
Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
E. Curtit (2011)
Trends in Phase II Trials for Cancer Therapies
Faruque Azam (2021)
Cytotoxic activity of Indian, Indonesian and UK plant extracts on breast cancer cells
S. Wagland (2015)
Prognostic Factors for Treatment Outcomes of First Line Chemotherapy in Metastatic Breast Cancer
H. Gamal (2011)
Gemcitabine-based chemotherapy as a viable option for treatment of advanced breast cancer patients: a meta-analysis and literature review
Zhibo Xie (2018)
Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway
Jianqin Lu (2018)
A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
A. Pallis (2012)
Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer.
V. Kaklamani (2017)
First-line Treatment of Metastatic Breast Cancer: Focus on Bevacizumab:
T. Fujii (2009)
Evaluación de tratamientos sistémicos en pacientes con cáncer de mama metastásico
Soriano García (2011)
Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis
D. Johansson (2008)
Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study
M. Gümüş (2012)
Computer Optimization of Stealth Biodegradable Polymeric Dual-Loaded Nanoparticles for Cancer Therapy using Central Composite Face-Centered Design.
Yvonne Berko (2020)
Can maintenance trastuzumab be stopped in patients with HER2-positive metastatic breast cancer?
A. Hsieh (2015)
Drug-eluting polymer implants in cancer therapy
A. Exner (2008)
Trends in Phase II trials for cancer therapies
F. Azam (2020)
In vitro chemosensitivity testing of primary and recurrent breast carcinomas and its clinical significance
Zhi Li 샮훎 (2008)
Drug Combinations in Breast Cancer Therapy
F. Fisusi (2019)
In vitro chemosensitivity testing of primary and recurrent breast carcinomas and its clinical significance
Z. Li (2008)
Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice
T. Zhang (2017)See more